Endocrine Balance
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
The FDA has approved the first gene therapy, Fayuvi, for Sanfilippo syndrome type A, offering hope to affected children.
By emily johnson · Sep 18, 2026
Tag: treatment
Nutrient Synergy
FDA Pilot Aims to Accelerate U.S. Drug Trials
The FDA's new pilot program aims to accelerate U.S. drug trials, reducing time from discovery to first-in-human studies.
By emily johnson · Sep 17, 2026
Endocrine Balance
Breast cancer drug Etcamah fails first-line trial test
AstraZeneca’s breast cancer drug Etcamah failed its first-line trial, SERENA-4, raising doubts about its potential as a frontline treatment for HR-positive pati
By emily johnson · Sep 15, 2026
Microbiome Diversity
Novo Nordisk drops name to sharpen focus amid Lilly rivalry
Novo Nordisk drops its full name to become 'Novo,' sharpening focus against Eli Lilly in weight loss and diabetes treatments amid slowing growth.
By emily johnson · Sep 14, 2026
Nutrient Synergy
AbbVie tests new approach for menstrual migraine treatment
AbbVie’s Qulipta becomes first oral CGRP inhibitor to succeed in phase 3 menstrual migraine trials, offering hope for resistant cases.
By Samoyed · Sep 12, 2026
Recovery Modalities
Bayer Moves Hyrnuo Into Frontline Lung Cancer
Bayer secured FDA approval for Hyrnuo lung cancer treatment, marking a major shift in frontline HER2-mutant NSCLC care based on new clinical data.
By Samoyed · Sep 10, 2026
Microbiome Diversity
Bristol Myers reports progress in multiple myeloma trial
Bristol Myers reports progress in multiple myeloma trial with arlocabtagene autoleucel showing promise.
By Samoyed · Sep 9, 2026
Microbiome Diversity
Guidelines for e-signature use in global trials
Guidelines for e-signature use in global trials, including qualified e-signature and standard e-signature options.
By emily johnson · Sep 8, 2026
Recovery Modalities
Sensorion gets green light for HearConnex trial
Sensorion's HearConnex trial gets green light for hearing loss treatment with gene therapy SENS-601.
By Samoyed · Sep 4, 2026
Nutrient Synergy
Alumis lupus drug advances after trial setback
Alumis advances its lupus drug to Phase III trials despite mixed Phase IIb results, targeting a specific patient subgroup for better outcomes.
By Samoyed · Sep 3, 2026